Journals / Türk Biyokimya Dergisi / 2019 / Cilt: 44 - Sayı: 5

The in vitro cytotoxicity, genotoxicity and oxidative damage potential of dapagliflozin, on cultured human blood cells

İnsan kan hücre kültürü üzerinde dapagliflozin’in in vitro sitotoksisite, genotoksisite ve oksidatif hasar potansiyeli

Pages
692–698
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Moreover, anyincrease in the frequency of CA did not found on culturesblood cells.Conclusion: These data indicate that DAPA has not cytotoxic and genotoxic potential in cultured human blood cells, also, induces the increasing antioxidant activity.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:AbstractObjectives: Dapagliflozin (DAPA), is a potent SGLT-2 inhibitor for the treatment of patients with type 2 diabetes.
📊
Key Findings & Data:The evaluation of the in vitro cytotoxicity, genotoxicity potential and antioxidant/oxidant activity of DAPA in primary human whole blood cell cultures was aimed in this study.Materials and methods: Cell viability was measured by the MTT [3,(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] and lactate dehydrogenase (LDH) leakage assays.
💡
Conclusion & Impact:Moreover, anyincrease in the frequency of CA did not found on culturesblood cells.Conclusion: These data indicate that DAPA has not cytotoxic and genotoxic potential in cultured human blood cells, also, induces the increasing antioxidant activity.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

AbstractObjectives: Dapagliflozin (DAPA), is a potent SGLT-2 inhibitor for the treatment of patients with type 2 diabetes. DAPA has a good clinical and biological tolerance profile. However little information is available on its potential effects on cultured human blood cells. The evaluation of the in vitro cytotoxicity, genotoxicity potential and antioxidant/oxidant activity of DAPA in primary human whole blood cell cultures was aimed in this study.Materials and methods: Cell viability was measured by the MTT [3,(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] and lactate dehydrogenase (LDH) leakage assays. The antioxidant/oxidant activity was determined by measuring the total antioxidant capacity (TAC) and total oxidative stress (TOS) levels. To assess the genotoxicity of DAPA, chromosomal aberration (CA) frequencies were determined.Results: MTT and LDH release assay exhibited that exposure to different doses of DAPA did not changed significantly the proliferation of cells. The results of TAC and TOS assays were showed that TAC level was elevated while TOSlevel did not altered in DAPA-treated cells. Moreover, anyincrease in the frequency of CA did not found on culturesblood cells.Conclusion: These data indicate that DAPA has not cytotoxic and genotoxic potential in cultured human blood cells, also, induces the increasing antioxidant activity.

Özet

ÖzAmaç: Dapagliflozin (DAPA), tip 2 diyabetli hastaların tedavisinde kullanılan güçlü bir SGLT-2 inhibitörüdür. DAPA iyi bir klinik ve biyolojik tolerans profiline sahiptir. Bununla birlikte, insan kan hücre kültürü üzerindeki potansiyel etkileri hakkında çok az bilgi bulunmaktadır. Bu çalışmada primer insan tam kan hücresi kültürlerinde DAPA’nın in vitro sitotoksisite, genotoksisite potansiyeli ve antioksidan/oksidan aktivitesinin değerlendirilmesi amaçlandı.Gereç ve yöntem: Hücre canlılığı, MTT [3,(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] ve laktat dehidrojenaz (LDH) sızıntı deneyleriyle ölçüldü. Antioksidan/oksidan aktivitesi, total antioksidan kapasite (TAC) ve total oksidatif stres (TOS) seviyeleri ölçülerek belirlendi. DAPA’nın genotoksisitesini değerlendirmek için kromozomal sapma (CA) frekansları belirlendi.Bulgular: MTT ve LDH salma deneyi, farklı DAPA dozlarına maruz kalmanın hücrelerin çoğalmasını önemli ölçüde değiştirmediğini gösterdi. TAC ve TOS testlerinin sonuçları, DAPA ile muamele edilen hücrelerde TOS seviyesi değişmediği halde TAC seviyesinin yükseldiğini gösterdi. Ayrıca, kan hücre kültürlerinde kromozomal sapma sıklığında herhangi bir artış bulunamamıştır.Sonuç: Bu veriler, DAPA’nın insan kan hücre kültürlerinde sitotoksik ve genotoksik potansiyele sahip olmadığını, ayrıca antioksidan aktivitenin artmasına neden olduğunu göstermektedir.

🔖

Cite This Article

TOZLU, Ö. Ö., Çadırcı, K., TÜRKEZ, H. (2022). The in vitro cytotoxicity, genotoxicity and oxidative damage potential of dapagliflozin, on cultured human blood cells. Türk Biyokimya Dergisi, Cilt: 44 - Sayı: 5, 692–698. https://ajindex.com/articles/620873

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (12)

  1. Prattichizzo F, De Nigris V, Spiga R, Mancuso E, La Sala L, Antonicelli R, et al. Inflammageing and metaflammation: the yin and yang of type 2 diabetes. Ageing Res Rev 2018;41:1–17
  2. Centers for Disease Control and Prevention. National diabetes statistics report: estimates of diabetes and its burden in the United States, 2017. Available from: https://www.cdc.gov/diabetes/pdfs/data/statistics/national-diabetes-statistics-report.pdf. Accessed June 09, 2018
  3. Chellappan DK, Yap WS, Bt Ahmad Suhaimi NA, Gupta G, Dua K. Current therapies and targets for type 2 diabetes mellitus. Panminerva Med 2018;60:117–31
  4. American Diabetes Association. Pharmacologic approaches to glycemic treatment. Diabetes Care 2017;40(Suppl 1):64–74
  5. Fioretto P, Giaccari A, Sesti G. Efficacy and safety of dapagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, in diabetes mellitus. Cardiovasc Diabetol 2015;14:142
  6. Rosenwasser RF, Sultan S, Sutton D, Choksi R, Epstein BJ. SGLT-2 inhibitors and their potential in the treatment of diabetes. Diabetes Metab Syndr Obes 2013;6:453–67
  7. Saeed MA, Narendran P. Dapagliflozin for the treatment of type 2 diabetes: a review of the literature. Drug Des Devel Ther 2014;8:2493–505
  8. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebocontrolled, phase 3 trial. Diabetes Care 2010;33:2217–24
  9. Strojek K, Yoon KH, Hruba V, Sugg J, Langkilde AM, Parikh S. Dapagliflozin added to glimepiride in patients with type 2 diabetes mellitus sustains glycemic control and weight loss over 48 weeks: a randomized, double-blind, parallel-group, placebocontrolled trial. Diabetes Ther 2014;5:267–83
  10. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care 2012;35:1473–8
  11. Sieuwerts AM, Klijn JG, Peters HA, Foekens JA. The MTT tetrazolium salt assay scrutinized: how to use this assay reliably to measure metabolic activity of cell cultures in vitro for the assessment of growth characteristics, IC50-values and cell survival. Eur J Clin Chem Clin Biochem 1995;33:813–23
  12. Cummings BS, Wills LP, Schnellmann RG. Measurement of cell death in mammalian cells. Curr Protoc Pharmacol 2012;Chapter 12:Unit12.8. doi: 10.100